BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b AND Treatment
34 results:

  • 1. FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance.
    Wang Z; Shen J; Chen C; Wen T; Li C
    Biosci Trends; 2023 May; 17(2):136-147. PubMed ID: 36823043
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
    van Eijck CWF; de Koning W; van der Sijde F; Moskie M; Groot Koerkamp B; Homs MYV; van der Burg SH; van Eijck CHJ; Mustafa DAM
    Eur J Cancer; 2023 Mar; 181():119-134. PubMed ID: 36652890
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.
    Yao C; Wu S; Kong J; Sun Y; Bai Y; Zhu R; Li Z; Sun W; Zheng L
    Cancer Biol Med; 2023 Jan; 20(1):25-43. PubMed ID: 36647777
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer.
    Shi YH; Xu QC; Zhu YQ; Liu ZD; Zhao GY; Liu Q; Wang XY; Wang JQ; Xu X; Su Q; Lai JM; Huang CS; Yin XY
    Mol Ther; 2023 Feb; 31(2):503-516. PubMed ID: 36384875
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. pancreatic ductal adenocarcinoma cells regulated the gemcitabine-resistance function of CAFs by LINC00460.
    Zhu XX; Li JH; Ni X; Wu X; Hou X; Li YX; Li SJ; Zhao W; Yin XY
    Cancer Sci; 2022 Nov; 113(11):3735-3750. PubMed ID: 36047966
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the treatment of cancer: A Review.
    Unnisa A; Chettupalli AK; Hussain T; Kamal MA
    Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Determining oncogenic patterns and cancer predisposition through the transcriptomic profile in Mitchell-Riley syndrome with heterotopic gastric mucosa and duodenal atresia: a case report.
    Calcaterra V; Chiricosta L; Mazzon E; Gugnandolo A; Alberti D; Maestri L; Meroni M; Vestri E; Verduci E; Dilillo D; Zuccotti G; Pelizzo G
    Orphanet J Rare Dis; 2021 Oct; 16(1):455. PubMed ID: 34715892
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Establishment of a 3D model of tumor-driven angiogenesis to study the effects of anti-angiogenic drugs on pericyte recruitment.
    Qiu Y; Wang N; Guo T; Liu S; Tang X; Zhong Z; Chen Q; Wu H; Li X; Wang J; Zhang S; Ou Y; Wang B; Ma K; Gu W; Cao J; Chen H; Duan Y
    Biomater Sci; 2021 Sep; 9(18):6064-6085. PubMed ID: 34136892
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Establishment and characterization of NCC-PLPS1-C1, a novel patient-derived cell line of pleomorphic liposarcoma.
    Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
    Hum Cell; 2021 Mar; 34(2):688-697. PubMed ID: 33205363
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results.
    Ueno M; Ikeda M; Sasaki T; Nagashima F; Mizuno N; Shimizu S; Ikezawa H; Hayata N; Nakajima R; Morizane C
    BMC Cancer; 2020 Nov; 20(1):1105. PubMed ID: 33198671
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Establishment and characterization of NCC-MLPS1-C1: a novel patient-derived cell line of myxoid liposarcoma.
    Noguchi R; Yoshimatsu Y; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
    Hum Cell; 2021 Mar; 34(2):667-674. PubMed ID: 33146842
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Design, synthesis, biological evaluation and molecular modeling study of new thieno[2,3-d]pyrimidines with anti-proliferative activity on pancreatic cancer cell lines.
    Salem MSH; Abdel Aziz YM; Elgawish MS; Said MM; Abouzid KAM
    Bioorg Chem; 2020 Jan; 94():103472. PubMed ID: 31813475
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Targeting Purinergic Receptor P2Y2 Prevents the Growth of pancreatic Ductal Adenocarcinoma by Inhibiting cancer Cell Glycolysis.
    Hu LP; Zhang XX; Jiang SH; Tao LY; Li Q; Zhu LL; Yang MW; Huo YM; Jiang YS; Tian GA; Cao XY; Zhang YL; Yang Q; Yang XM; Wang YH; Li J; Xiao GG; Sun YW; Zhang ZG
    Clin Cancer Res; 2019 Feb; 25(4):1318-1330. PubMed ID: 30420446
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Melatonin Synergizes with Sorafenib to Suppress pancreatic cancer via Melatonin Receptor and pdgfr-β/STAT3 Pathway.
    Fang Z; Jung KH; Yan HH; Kim SJ; Rumman M; Park JH; Han B; Lee JE; Kang YW; Lim JH; Hong SS
    Cell Physiol Biochem; 2018; 47(5):1751-1768. PubMed ID: 29953970
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Masitinib in treatment of pancreatic cancer.
    Waheed A; Purvey S; Saif MW
    Expert Opin Pharmacother; 2018 May; 19(7):759-764. PubMed ID: 29638149
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype.
    Keutgen XM; Kumar S; Gara SK; Boufraqech M; Agarwal S; Hruban RH; Nilubol N; Quezado M; Finney R; Cam M; Kebebew E
    Cancer; 2018 Feb; 124(3):636-647. PubMed ID: 29149451
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Cotargeting of MEK and pdgfr/STAT3 Pathways to Treat pancreatic Ductal Adenocarcinoma.
    Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
    Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Antiangiogenic Therapy in pancreatic Neuroendocrine Tumors.
    Capozzi M; VON Arx C; DE Divitiis C; Ottaiano A; Tatangelo F; Romano GM; Tafuto S;
    Anticancer Res; 2016 Oct; 36(10):5025-5030. PubMed ID: 27798861
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Impact of p53 and pdgfr-β Expression on Metastasis and Prognosis of Patients with pancreatic cancer.
    Kurahara H; Maemura K; Mataki Y; Sakoda M; Shinchi H; Natsugoe S
    World J Surg; 2016 Aug; 40(8):1977-84. PubMed ID: 26940582
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (pdgfr-α, pdgfr-β, and c-kit).
    Moawad EY
    J Gastrointest Cancer; 2015 Sep; 46(3):272-83. PubMed ID: 25985771
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.